BARDA Awarded $96 Million for Nerve Agent Auto-Injectors
The federal contract funds the development and production of pralidoxime chloride injectors for national chemical preparedness.
Updated on Oct. 13, 2026 in Biotech
Live Poll
Does government funding for private pharmaceutical companies effectively improve national chemical threat preparedness?
The Biomedical Advanced Research and Development Authority (BARDA) has awarded a $96.1 million contract to Kaléo for the development and initial procurement of auto-injectors. These devices are intended to treat nerve agent or organophosphate poisoning as part of the federal CHEMPACK program.
Why it matters
This contract strengthens national biodefense capabilities by ensuring the availability of specialized medical countermeasures for chemical threats. The funding enables late-stage development and manufacturing validation for technology that reverses the effects of hazardous nerve agents.
The auto-injector delivers pralidoxime chloride, a medication that restores acetylcholinesterase activity in the body. The contract provides $96.1 million for development and validation, with potential future options totaling $244.8 million.
The players
BARDA
The Biomedical Advanced Research and Development Authority is a U.S. government agency focused on the advanced research, development, and procurement of medical countermeasures for health security threats.
Kaléo
A Virginia-based pharmaceutical company specializing in the development of drug-device combinations, including auto-injector platforms for emergency medicine.
The details
The auto-injector functions by delivering pralidoxime chloride to neutralize the chemical effects of organophosphates. These agents work by inhibiting acetylcholinesterase — an enzyme critical for proper nerve signal transmission. By restoring this enzymatic activity, the device prevents the persistent nerve stimulation caused by exposure to toxic compounds.
Timeline
BARDA and Kaléo initiated a prior collaborative effort in 2024.
Kaléo out-licensed its auto-injector technology to Amgen in August 2026.
The federal contract was officially awarded on October 13, 2026.
The Tech Race
This development integrates new injection hardware into the existing CHEMPACK national emergency response infrastructure. It follows a trajectory of sustained government investment in rapid-response medical devices to address volatile chemical threat landscapes.
These auto-injectors are reserved for inclusion in the national CHEMPACK stockpile and are not available for direct purchase by individual consumers. The technology will be utilized by emergency responders and public health authorities to manage large-scale chemical exposures.
The takeaway
This award marks a shift toward securing decentralized medical stockpiles against chemical incidents. Stakeholders should monitor the progression of FDA regulatory milestones and the eventual integration of these devices into regional emergency kits.
Further reading
For broader context on federal medical development initiatives, see the Biotech section.
Source note: This article includes information reported by FiercePharma.
Live Poll
Does government funding for private pharmaceutical companies effectively improve national chemical threat preparedness?
